Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SYDNEY, Australia, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”), announced today that the Database Safety Monitoring Board (“DSMB”)...
-
SYDNEY, Australia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) announced today that it has received a milestone payment from the Company’s Chinese partner for...
-
SYDNEY, Australia, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (Immutep or the Company), has provided an update on the Company’s two ongoing clinical trials with...
-
SYDNEY, Australia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- We refer to shareholder approval granted at the Company’s Annual General Meeting held on 17 November 2017 to change the name of the Company from...
-
SYDNEY, Australia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”) announces the grant of patent number 2604275 entitled “Use of Recombinant LAG-3...
-
SYDNEY, Australia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) has announced a rebranding of the Company from Prima BioMed Ltd to Immutep...
-
SYDNEY, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) is pleased to announce that it held a Pre-Investigational New Drug Application (pre-IND)...
-
SYDNEY, Australia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial...
-
SYDNEY, Australia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer and Medical Officer,...
-
SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ: PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer,...